<DOC>
	<DOCNO>NCT00107900</DOCNO>
	<brief_summary>Patients undergo total hip replacement surgery great risk get deep vein thrombosis ( blood clot ) . This study evaluate safety , tolerability effectiveness study drug , DU-176b , reduce occurrence deep vein thrombosis patient total hip replacement surgery .</brief_summary>
	<brief_title>Study Efficacy Safety DU-176b Preventing Blood Clots Patients Undergoing Total Hip Replacement</brief_title>
	<detailed_description>The primary study objective demonstrate prevention venous thromboembolism patient undergoing total hip replacement surgery . The secondary objective ass safety tolerability DU-176 .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Unilateral hip replacement Patients schedule bilateral hip replacement procedure Patients increase risk bleeding Uncontrolled hypertension ( BP great 180/100 mmHg ) Patients less 111 lb 243 lb Patients longterm anticoagulant Patients contraindication venography Patients medical history venous thromboembolism Patients impaired hepatic function Known pregnant Lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Deep Vein Thrombosis ,</keyword>
	<keyword>Anticoagulant ,</keyword>
	<keyword>Venous thromboembolic</keyword>
</DOC>